Qlaris Phase 2 Study of QLS-111 in POAG And/or OHT Patients

Inclusion Criteria: * 18 years or older * Able to provide written acknowledgement of giving informed consent * Best corrected visual acuity (BCVA) 20/200 or better Bilateral POAG or OHT with documented historic IOP value(s) ≥24 mmHg, in either eye * Post-washout IOP ≥22 mmHg in morning on Visits 2 and 3 and ≥18 mmHg at noon on Visit 2 Exclusion Criteria: * IOP \>34 mmHg * Severe glaucomatous damage that would preclude safe washout of prescribed ocular hypotensive medications * Previous glaucoma surgery, certain procedures (trabeculotomy, shunt/tubes, cyclodestructive procedure) (selective laser trabeculoplasty (SLT) allowed if done no earlier than 1 year from study, some minimally invasive glaucoma surgeries are allowed if done no earlier than 1 year from study) * Ocular trauma, ocular infections, ocular inflammation, herpes simplex keratitis of eye * Use of other ophthalmic concomitant medications during the study * Uncontrolled hypertension or hypotension * Significant systemic or psychiatric disease * Participation in other investigational trial 30 days prior to screening or previous enrollment and treatment with Qlaris investigational product * Pregnant or lactating